<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cognitive enhancement supplements</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cognitive enhancement supplements</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cognitive enhancement supplements</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent name</td> <td class="subtitle1">Alternative name(s) listed on supplement label</td> <td class="subtitle1">Proposed mechanism of activity</td> <td class="subtitle1">Potential adverse effects</td> </tr> <tr> <td>Vinpocetine</td> <td>Lesser periwinkle, <em>Vinca minor</em>, Cavinton, apovincaminic acid, creeping myrtle</td> <td>Vasodilator</td> <td>Flushing, headaches, and decreased blood <span class="nowrap_whitespace">pressure<sup>[1,2]</sup></span></td> </tr> <tr> <td>Picamilon</td> <td>N-nicotinyl-y-aminobutyric acid, pikamilon, pikamilone, pikatropin, pycamilon</td> <td>GABA agonist; derived from GABA</td> <td>May be similar to <span class="nowrap_whitespace">gabapentin<sup>[3]</sup></span></td> </tr> <tr> <td>Phenibut</td> <td>B-phenyl-y-aminobutyric acid, phenigam, PhGaba, Phenigamma, Phenygam, phenyl-GABA</td> <td>GABA-B agonist</td> <td>Lethargy, agitation, tachycardia, confusion, dependence. With overdose, delirium, psychosis, and <span class="nowrap_whitespace">coma.<sup>[4-6]</sup></span></td> </tr> <tr> <td>Huperzine A</td> <td><em>Huperzia serrata</em> extract, HupA, <em>Huperzia selago</em> extract, Sealgine</td> <td>Anticholinesterase inhibitor</td> <td>Similar to prescription cholinesterase inhibitors (eg, GI [nausea, diarrhea, vomiting], increased urination, muscle cramps). Avoid concomitant use of prescription cholinesterase inhibitors as this increases the risk of adverse <span class="nowrap_whitespace">effects.<sup>[7,8]</sup></span></td> </tr> <tr> <td>Piracetam</td> <td>Barcan, Noostan, Nootrop, Nootropil, Nootropyl, Normabra√Øn, pyrrolidone acetamide</td> <td>Antimyoclonic; modulates CNS neurotransmission (eg, cholinergic and glutamatergic)</td> <td>Anxiety, insomnia, agitation, sleepiness, weight gain, <span class="nowrap_whitespace">depression<sup>[9,10]</sup></span></td> </tr> <tr> <td>Omberacetam</td> <td>Noopept, N-phenylacetyl-L-prolylglycine ethyl ester, ethyl phenylacetyl-Pro-Gl</td> <td>Activation of HIF 1</td> <td>Unknown<sup>[11]</sup></td> </tr> <tr> <td>Aniracetam</td> <td>Draganon</td> <td>Ampakine, potentiates neurotransmission via AMPA-type glutamate receptors</td> <td>Unknown<sup>[11,12]</sup></td> </tr> <tr> <td>Meclofenoxate</td> <td>Centrophenoxine</td> <td>Cholinergic agent</td> <td>Unknown<sup>[13,14]</sup></td> </tr> <tr> <td>Levodopa</td> <td>L-dopa, <em>Mucuna pruriens</em> <span class="nowrap_whitespace">extract,<sup>[15]</sup></span> cowhage</td> <td>Dopamine precursor. NOTE: Limited entrance of levodopa into CNS without co-administration of peripheral dopa-decarboxylase inhibitor (eg, carbidopa).</td> <td>Nausea, vomiting, sleepiness, orthostatic hypotension, confusion, hallucinations</td> </tr> <tr> <td>Tianeptine</td> <td>Coaxil, Stablon</td> <td>Atypical antidepressant with various CNS receptor actions</td> <td>Dependence and abuse potential. Agitation, drowsiness, confusion, sweating, rapid heartbeat, high blood pressure, nausea, vomiting, slowed breathing, coma, and <span class="nowrap_whitespace">death.<sup>[16]</sup></span></td> </tr> <tr> <td>Kratom</td> <td><em>Mitragyna speciosa</em></td> <td>CNS mu-opioid receptor agonist properties</td> <td>Dependence and abuse potential, respiratory depression, anorexia, depression, psychosis, <span class="nowrap_whitespace">seizures<sup>[17]</sup></span></td> </tr> <tr> <td>CBD</td> <td>Cannabidiol</td> <td>Unknown; appears to inhibit CNS neurotransmission; may mimic effects of endogenous cannabinoid compounds</td> <td>Diarrhea, somnolence, decreased appetite, increased transaminases. Potential THC and synthetic cannabinoid <span class="nowrap_whitespace">exposure.<sup>[18,19]</sup></span></td> </tr> </tbody></table></div><div class="graphic_lgnd">Testing of dietary supplements often reveals drugs not declared on labeling, labeled drugs/herbs not detected in the product, inaccurate quantities, and adulteration with prescription and experimental drugs. In addition, doses contained in supplements may far exceed pharmaceutical quantities, increasing the risks of adverse effects. For review of health risks and an approach to patient counseling, refer to UpToDate topic reviews of high-risk dietary supplements.</div><div class="graphic_footnotes">GABA: gamma-aminobutyric acid; GI: gastrointestinal; HIF: hypoxia-inducible factor; CNS: central nervous system; CBD: cannabidiol; THC: delta-9-tetrahydrocannabinol.</div><div class="graphic_reference">References:
	<ol>
<li>Cohen PA. Vinpocetine: An unapproved drug sold as a dietary supplement. Mayo Clin Proc 2016; 90:1455.</li>
<li>National Toxicology Program. Chemical information review document for vinpocetine. Available at: https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/vinpocetine091613_508.pdf (Accessed on July 13, 2022).</li>
<li>Avula B, Chittboyina AG, Sagi S, et al. Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. Drug Test Anal 2016; 8:334.</li>
<li>Cohen PA, Ellison RR, Travis JC, et al. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila) 2022; 60:486.</li>
<li>Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the field: Phenibut exposures reported to poison centers - United States, 2009-2019. MMWR Morb Mortal Wkly Rep 2020; 69:1227.</li>
<li>McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med 2019; 37:2066.</li>
<li>Crawford C, Wang YH, Avula B, et al. The scoop on brain health dietary supplement products containing huperzine A. Clin Toxicol (Phila) 2020; 58:991.</li>
<li>Alzheimer's Association. Taking control: A guide for early-stage Alzheimer's disease. Available at: https://www.alz.org/media/manh/documents/alzhiemer_s-taking-control-guide-(tcg).pdf (Accessed on July 13, 2022).</li>
<li>Winblad B. Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev 2005; 11:169.</li>
<li>Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Intern Med 2020; 180:458.</li>
<li>Cohen PA, Avula B, Wang YH, et al. Five unapproved drugs found in cognitive enhancement supplements. Neurol Clin Pract 2021; 11:e303.</li>
<li>Martin JR, Haefely WE. Pharmacology of Aniracetam. Drug Invest 1993; 5:4.</li>
<li>Zou JJ, Ji HJ, Wu DW, et al. Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. Clin Ther 2008; 30:1651.</li>
<li>Cohen PA, Avula B, Khan I. The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements. Clin Toxicol (Phila) 2022.</li>
<li>Cohen PA, Avula B, Katragunta K, et al. Levodopa content of Mucuna pruriens supplements in the NIH Dietary Supplement Label Database. JAMA Neurol 2022.</li>
<li>US Food and Drug Administration. Tianeptine products linked to serious harm, overdoses, death. February 2022. Available at: https://www.fda.gov/consumers/consumer-updates/tianeptine-products-linked-serious-harm-overdoses-death (Accessed on July 13, 2022).</li>
<li>US Food and Drug Administration. FDA and kratom. Available at: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom (Accessed on July 13, 2022).</li>
<li>Rianprakaisang T, Gerona R, Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clinical Toxicol (Phila) 2020; 58:215-216.</li>
<li>Cohen PA, Sharfstein J. Perspective: The opportunity of CBD ‚Äî reforming the law. N Engl J Med 2019; 381:297.</li>
</ol></div><div id="graphicVersion">Graphic 139128 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
